Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04930653 · ClinicalTrials.gov registry record · Phase 2

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

A Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 2
Development phase
34
Enrollment target
3
Study locations

NCT04930653: Recruiting Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, sponsored by City of Hope Medical Center.

NCT04930653 is a Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 34 participants, below the 80-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04930653, a Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
34 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).

Primary Outcome

ORR will be calculated as the proportion of evaluable patients that have confirmed complete response (CR) or partial response (PR), as defined according to global response assessment. Exact 95% confidence intervals will be calculated for these estimates.

Conditions Studied

Sezary Syndrome Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 Folliculotropic Mycosis Fungoides Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 Transformed Mycosis Fungoides Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Questionnaire Administration
  • BIOLOGICAL Mogamulizumab
  • PROCEDURE Extracorporeal Photopheresis

Study Locations (3)

Arizona

  • Mayo Clinic - Scottsdale

California

  • City of Hope Medical Center - Duarte

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2022-10-19
Est. Completion 2028-06-15
Phase Phase 2
City of Hope Medical Center

582 total trials

What NCT04930653 shows while recruiting

NCT04930653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 80-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (57% lower).

The record links to 8 conditions, with Sezary Syndrome appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04930653 reports a single indexed study location in Arizona, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT04930653 about?

NCT04930653 is a clinical study titled "Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma". This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a wide...

What is the current status of trial NCT04930653?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2022-10-19. Estimated completion is 2028-06-15.

What conditions does trial NCT04930653 study?

This clinical trial studies the following conditions: Sezary Syndrome, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Folliculotropic Mycosis Fungoides, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8.

What interventions are being tested in trial NCT04930653?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Mogamulizumab (BIOLOGICAL), Extracorporeal Photopheresis (PROCEDURE).

Who is sponsoring clinical trial NCT04930653?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04930653 being conducted?

This trial has 3 study locations across Arizona, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sezary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04930653's enrollment target sits among peer trials

34 7th of 13 higher than 7 of 13 other Sezary Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sezary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04930653

Source: ClinicalTrials.gov NCT04930653, the US trial registry maintained by the National Library of Medicine. NCT04930653 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.